Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Satellos Bioscience Inc T.MSCL

Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and... see more

Bullboard (TSX:MSCL)

View:
Comment by G1945Von Nov 04, 2024 7:53am

RE:Webinar Recap: $MSCL CEO Frank Gleeson and CFO Liz Williams

Satellos to Participate in November 2024 Investor Conferences
Post by bmreedon Sep 28, 2024 8:04pm

Webinar $MSCL CEO Frank Gleeson Oct 3 @ 1PM ET / 10AM PT

Live Webinar - Satellos Bioscience (MSCL) CEO Frank Gleeson and CFO Elizabeth Williams Thursday, October 3rd at 1PM ET / 10AM PT Q&A with Radius Research  Register Here - https ...more  
Post by G1945Von Jul 11, 2024 10:26am

Filing to Commence a Phase 1 Clinical Trial

Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247  
Post by G1945Von Jul 02, 2024 7:59am

Preliminary Data Muscle Repair

Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy ("DMD") G1945V
Post by bmreedon May 21, 2024 11:51am

Webinar $MSCL CEO Frank Gleeson May 23 @ 2PM ET / 11AM PT

Live Webinar - Satellos Bioscience Inc. (MSCL) w/ CEO Frank Gleeson Thursday, May 23rd at 2PM ET / 11AM PT Q&A with Radius Research  Register Here - https://us02web.zoom.us/webinar ...more  
Post by Drambueyon Apr 24, 2024 3:10pm

Post deleted SNOWFLAKES MANAGEMENT

So you deleted my post did it hit too close to home SNOWFLAKE MANAGEMENT?  Let me get this straight you roll back the stock 20 to one collect $1.4 million in salaries and the stock is trading at  ...more  
Comment by G1945Von Apr 24, 2024 7:13am

RE:You want to do what, AGAIN?

"you want to pass a resolution to roll this back again" Where is this coming from? G1945V
Post by beenthereon Mar 12, 2024 4:51pm

Sure Glad The Boys Moved To The TSX

Hate to think where we would be without that move!
Comment by beenthereon Jan 25, 2024 5:46pm

RE:Great day for Satellos

Yes for sure! It's definitely your lucky day!  lol Can I ask if you researched this company at all? Did you check the background of where this company came from? Did you check to see ...more  
Post by JohnnyChanginiton Jan 16, 2024 11:05am

Great day for Satellos

The TSX lising and prestigious award/recognition in one day! Soo glad I own this and just adding!
Post by G1945Von Jan 16, 2024 10:02am

BUSINESS WIRE

Satellos Receives Conditional Approval to Graduate to the Toronto Stock Exchange G1945V
Post by Drambueyon Nov 21, 2023 4:51pm

15,000 gets you……..

Up 23% back to the price which the stock was trading at when they hired ICP Securities Inc.  Christmas bonuses all around lol
Post by Drambueyon Nov 01, 2023 4:55pm

What does $7,500 a month get you

Stock price down 23% since signing ICP Securities marketing services.   
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities